Company intelligence / Profile preview

Vion Pharmaceuticals

New Haven, Connecticut, United Statesnrc.gov ↗

Ownership: Private
Development stage: Phase 3

Overview

The company developed small molecule oncology drugs, most notably laromustine (VNP40101M), a sulfonylhydrazine alkylating agent. Clinical trials included combinations with cytarabine for AML and MDS, but the company ceased operations following bankruptcy and delisting from Nasdaq in August 2008. No products reached commercialization.

Therapeutic areas: OncologyHematology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

5 assets

laromustine

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Vion Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vion Pharmaceuticals.

Explore the full profile